SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934
(Amendment No. 2)*

CNBX Pharmaceuticals Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

13764M209

(CUSIP Number)

September 30, 2024

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☒ Rule 13d-1(c)
☐ Rule 13d-1(d)

^*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 13764M209

13G

Page 2 of 9 Pages


1.	NAMES OF REPORTING PERSONS 3i, LP
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☒ (b) ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 3,340,428 (1)
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 3,340,428 (1)

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,340,428 (1)
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9% (1)
12.	TYPE OF REPORTING PERSON (see instructions) PN

(1) As more fully described in Item 4 of this Amendment No. 2 to Schedule 13G (the “Amendment No. 2”), such shares and percentage are based on 31,111,352 shares of common stock, par value $0.0001 per share, of the issuer (the “Common Stock”) outstanding, as disclosed in the issuer’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2024, filed with the U.S. Securities and Exchange Commission on July 15, 2024 (the “Form 10-Q”), and do not give effect to all of the shares of Common Stock issuable upon full conversion of a senior secured convertible note (the “Note”) directly held by the reporting person, which conversion is subject to a 9.99% beneficial ownership limitation provision.

CUSIP No. 13764M209

13G

Page 3 of 9 Pages


1.	NAMES OF REPORTING PERSONS 3i Management LLC
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☒ (b) ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 3,340,428 (1)
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 3,340,428 (1)

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,340,428 (1)
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9% (1)
12.	TYPE OF REPORTING PERSON (see instructions) OO

(1) As more fully described in Item 4 of this Amendment No. 2, such shares and percentage are based on 31,111,352 shares of Common Stock outstanding, as disclosed in the Form 10-Q, and do not give full effect to all of the shares of Common Stock issuable upon full conversion of the Note indirectly held by the reporting person, which conversion is subject to a 9.99% beneficial ownership limitation provision.

CUSIP No. 13764M209

13G

Page 4 of 9 Pages


1.	NAMES OF REPORTING PERSONS Maier Joshua Tarlow
2.	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) ☒ (b) ☐
3.	SEC USE ONLY
4.	CITIZENSHIP OR PLACE OF ORGANIZATION United States

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 3,340,428 (1)
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER 3,340,428 (1)

9.	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 3,340,428 (1)
10.	CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) ☐
11.	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.9% (1)
12.	TYPE OF REPORTING PERSON (see instructions) IN

(1) As more fully described in Item 4 of this Amendment No. 2, such shares and percentage are based on 31,111,352 shares of Common Stock outstanding, as disclosed in the Form 10-Q, and do not give effect to all of the shares of Common Stock issuable upon full conversion of the Note indirectly held by the reporting person, which conversion is subject to a 9.99% beneficial ownership limitation provision.

CUSIP No. 13764M209

13G

Page 5 of 9 Pages

This Amendment No. 2 to Statement on Schedule 13G (this “Amendment No. 2”) amends and supplements the Amendment No. 1 to Statement on Schedule 13G filed by the reporting persons with the U.S. Securities and Exchange Commission (“SEC”) on February 13, 2024 (the “Amendment No. 1”), which amended and supplemented the Statement on Schedule 13G filed by the reporting persons with the SEC on March 6, 2023 (together with Amendment No. 1, the “Schedule 13G”). The purpose of this Amendment No. 2 is to update the beneficial ownership information on the cover pages and in Item 4 in the Schedule 13G.

Item 1(a). Name of Issuer:

CNBX Pharmaceuticals Inc. (the “Issuer”).

Item 1(b). Address of Issuer’s Principal Executive Offices:

The Issuer’s principal executive offices are located at #3 Bethesda Metro Center, Suite 700, Bethesda, MD 20814.

Item 2(a). Names of Persons Filing:

This Amendment is filed by:

	(i)	3i, LP, a Delaware limited partnership (“3i”);

	(ii)	3i Management LLC, a Delaware limited liability company (“3i Management”); and

	(iii)	Maier Joshua Tarlow (“Mr. Tarlow”).

The foregoing persons are hereinafter sometimes collectively referred to as the “Reporting Persons”. Any disclosures herein with respect to persons other than the Reporting Persons are made on information and belief after making inquiry to the appropriate party.

The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed as Exhibit 1 to the Schedule 13G, pursuant to which they have agreed to file the Schedule 13G, this Amendment No. 2 and all subsequent amendments jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

The filing of this Amendment No. 2 should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein.

Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business address of each of the Reporting Persons is 2 Wooster Street, 2^nd Floor, New York, NY 10013.

Item 2(c). Citizenship:

3i is a Delaware limited partnership. 3i Management is a Delaware limited liability company. Mr. Tarlow is a citizen of the United States.

Item 2(d). Title of Class of Securities:

The title of the class of securities to which this Amendment No. 2 and the Schedule 13G relate is the Issuer’s common stock, par value $0.0001 per share.

Item 2(e). CUSIP Number: 13764M209

CUSIP No. 13764M209

13G

Page 6 of 9 Pages

Item 3. If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

Not applicable.

Item 4. Ownership.

The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Amendment No. 2 and is incorporated herein by reference for each such Reporting Person. The ownership percentages reported are based on (i) 31,111,352 shares of Common Stock outstanding, as disclosed in the issuer’s Quarterly Report on Form 10-Q for the fiscal period ended May 31, 2024, filed with the SEC on July 15, 2024, and (ii) a senior secured convertible note held by 3i in the principal amount of $879,985 (the “Note”), which conversion is subject to a 9.99% beneficial ownership limitation provision.

3i holds (i) 1,014,059 shares of Common Stock and (ii) the Note convertible for up to 2,326,369 shares of Common Stock, assuming conversion at the alternate conversion price of the Note, which is subject to a 9.99% beneficial ownership limitation provision, which prohibits the holder thereof from exercising the Note for shares of Common Stock if, as a result of such exercise, such holder, together with its affiliates and any persons acting as a group together with such holder or any such affiliates, would beneficially own more than 9.99% of the total number of shares Common Stock then issued and outstanding immediately after giving effect to such exercise.

Consequently, 3i is the beneficial owner of 3,340,428 shares of Common Stock (the “Shares”). 3i has the power to dispose of and the power to vote the Shares beneficially owned by it, which power may be exercised by 3i Management, the manager and general partner of 3i. Mr. Tarlow, as the manager of 3i Management, has shared power to vote and/or dispose of the Shares beneficially owned by each of 3i and 3i Management. Mr. Tarlow does not directly own the Shares. By reason of the provisions of Rule 13d-3 of the Act, Mr. Tarlow may be deemed to beneficially own the Shares beneficially owned by 3i and 3i Management, and 3i Management may be deemed to beneficially own the Shares beneficially owned by 3i.

Item 5. Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of Members of the Group.

See Exhibit 1 filed with the Schedule 13G.

Item 9. Notice of Dissolution of Group.

Not applicable.

CUSIP No. 13764M209

13G

Page 7 of 9 Pages

Item 10. Certification.

By signing below each of the Reporting Persons certify that, to the best of each of their knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

CUSIP No. 13764M209

13G

Page 8 of 9 Pages

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: November 14, 2024	3i, LP

	By:	3i Management LLC,
		its General Partner

	By:	/s/ Maier J. Tarlow
		Name: Maier J. Tarlow
		Title: Manager

	3i Management LLC

	By:	/s/ Maier J. Tarlow
		Name: Maier J. Tarlow
		Title: Manager

	/s/ Maier J. Tarlow
	Maier J. Tarlow

CUSIP No. 13764M209

13G

Page 9 of 9 Pages

LIST OF EXHIBITS

Exhibit No.		Description

1		Joint Filing Agreement, dated March 6, 2023(incorporated by reference to Exhibit 1 to the Schedule 13G filed by the Reporting Persons with the SEC on March 6, 2023.

CNBX Pharmaceuticals Inc. SC 13G/A